A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
Status:
Completed
Trial end date:
2010-07-28
Target enrollment:
Participant gender:
Summary
This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic
inflammation. The study will investigate the paradigm of multiple receptor antagonism in
allergic disease by combining QAV680 with a second generation H1 histamine receptor
antagonist to assess possible additive or synergistic anti-allergic effects of the two
compound classes.